# CroiValve

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/croivalve

- Industry: Medical Devices & Equipment
- Headquarters: Dublin, Ireland
- Website: www.croivalve.com
- Total disclosed funding: $34M
- Latest round: Series B (Jun 23, 2026)
- Investors on record: 13

## About

CroiValve is a medical technology company focused on developing advanced solutions for the treatment of severe Tricuspid Regurgitation, providing innovative options for improving patient outcomes in cardiovascular care.

Based in Dublin, Ireland and founded in 2016, CroíValve Limited provides transcatheter cardiovascular devices for the structural heart disease market. The company develops innovative solutions for treating tricuspid regurgitation, a condition associated with significant morbidity and limited treatment options. CroíValve was founded by Fionn Lahart, who continues to lead the company as a CEO. In June 2026, CroiValve raised USD 20 million in series B funding from BGF Investment Management and European Innovation Council, with participation from  Medtech Syndicate. The round was part of a larger USD 43 million series B and grant funding. The round was part of a larger USD 43 million series B and grant funding.

The company works with physicians, hospitals, and cardiovascular specialists to provide transcatheter therapies for patients with tricuspid regurgitation. CroíValve’s flagship product is the DUO™ Adapt System, an investigational transcatheter heart valve designed to preserve native valve anatomy while reducing regurgitation. The technology utilizes an adaptive coaptation approach that accommodates varying leak geometries and complex patient anatomies. The company’s engineers, clinical specialists, regulatory professionals, and research teams support device development, clinical validation, and regulatory activities. Its solutions target structural heart disease treatment within the global interventional cardiology and medical technology markets.

The company’s revenue is generated by future commercialization opportunities associated with its structural heart disease technologies and related medical device products. CroíValve develops proprietary transcatheter valve technologies intended for use by hospitals, cardiac centers, and healthcare providers. Its business model is centered on advancing clinical evidence, securing regulatory approvals, and establishing partnerships with healthcare systems and medical technology stakeholders. The company also benefits from non-dilutive grant funding programs that support research, development, and clinical study activities.

The company will use the June 2026 funding to fund an expanded TANDEM II Study evaluating the DUO Adapt System in patients with severe symptomatic tricuspid regurgitation and to expand the study across additional U.S. and European sites.

## Funding rounds

- Series B, Jun 23, 2026, $20M — BGF Investment Management, European Innovation Council, Medtech Syndicate
- Series A, Dec 21, 2021, $8.7M — Atlantic Bridge, Enterprise Ireland, Broadview Ventures, Furthr, Irrus Investments, Halo Business Angel Network, Elkstone Ventures, Furthr VC, Ascentifi Limited
- Series A, Aug 27, 2019, $1.6M — Atlantic Bridge, Broadview Ventures, SOSV, Irrus Investments, Halo Business Angel Network
- Seed, Dec 21, 2018, $3.7M — Atlantic Bridge, Enterprise Ireland, SOSV, Irrus Investments, Halo Business Angel Network

## Investors

- Atlantic Bridge (https://capitalatlas.ai/funds/atlantic-bridge) — Seed, Series A
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Seed, Series A
- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- Irrus Investments — Seed, Series A
- Halo Business Angel Network — Seed, Series A
- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series A
- Furthr (https://capitalatlas.ai/funds/furthr) — Series A
- Elkstone Ventures (https://capitalatlas.ai/funds/elkstone-ventures) — Series A
- Furthr VC (https://capitalatlas.ai/funds/furthr-vc) — Series A
- Ascentifi Limited (https://capitalatlas.ai/funds/ascentifi-limited) — Series A
- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B
- Medtech Syndicate — Series B